Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT
Authors' conclusion
Icosapent ethyl demonstrated significant benefits in coronary physiology compared with placebo.
Study context
- Population
- Patients from EVAPORATE with coronary computed tomography angiography (CTA) and FFRCT at baseline, 9 and 18 months
- Participants
- 47 patients507 coronary lesions
- Comparison
- Icosapent ethyl (IPE) vs placebo
- Primary endpoint
- Change in distal coronary segment FFRCT in the most diseased vessel per patient
- Follow-up
- Baseline to (9 and 18 months)
Methodological detailsblinded core lab, pre-specified endpoints
- Blinded core lab
- Pre-specified endpoints
Primary result
As reported in the abstract
Change in distal segment FFRCT · 9 and 18 months
| Group | Value | 18 months |
|---|---|---|
| IPE | mean 0.01 (SD 0.05) | −0.01 ± 0.09 |
| Placebo | mean −0.05 (SD 0.09) | −0.09 ± 0.12 |
Value
IPEmean 0.01 (SD 0.05)
Placebomean −0.05 (SD 0.09)
18 months
IPE−0.01 ± 0.09
Placebo−0.09 ± 0.12
- IPE vs Placebo: P = 0.02 — 9 months
- IPE vs Placebo: P = 0.03 — 18 months
Secondary outcomes
| Outcome | IPE | Placebo | P value |
|---|---|---|---|
| Baseline FFRCT | 0.83 (SD 0.08) | 0.84 (SD 0.08) | P = 0.55 |
| Change in translesional FFRCT (ΔFFRCT) across most severe lesion (≥30% stenosis) per vesselNot statistically significant | −0.06 (SD 0.08) | −0.09 (SD 0.1) | P = 0.054 |
- Change in translesional FFRCT (ΔFFRCT) across most severe lesion (≥30% stenosis) per vessel: 140 coronary lesions
Original publication
Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT. Eur Heart J Cardiovasc Imaging. Published 22 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →